The impact of p53 and p73 on aneuploidy and cancer

Trends in Cell Biology

Volumn 18, Issue 5, 2008, Pages 244-252

  Tomasini, Richard ^a,b   Mak, Tak W ^b   Melino, Gerry ^c,d  

^a INSERM   (France)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN P73; TUMOR SUPPRESSOR PROTEIN;

ANEUPLOIDY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME; MITOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATOR GENE; REVIEW; TUMOR CELL; TUMOR GENE;

ANEUPLOIDY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; MICE; MITOSIS; NEOPLASMS; NUCLEAR PROTEINS; PHENOTYPE; PLOIDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 42749084082     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2008.03.003     Document Type: Review

References (85)

1. Yang A., et al. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18 (2002) 90-95
2. Lane D.P., and Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278 (1979) 261-263
3. Linzer D.I., and Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17 (1979) 43-52
4. Petitjean A., et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
5. Yang A., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominantnegative activities. Mol. Cell 2 (1998) 305-316
6. Kaghad M., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
7. Yang A., and McKeon F. p63 and p73: p53 mimics, menace and more. Nat. Rev. Mol. Cell Biol. 1 (2000) 199-207
8. Gong J.G., et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399 (1999) 806-809
9. Melino G., et al. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2 (2002) 605-615
10. Koster M.I., et al. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18 (2004) 126-131
11. Candi E., et al. Differential roles of p63 isoforms in epidermal devlopment: selective genetic complementation in p63 null mice. Cell Death Differ. 13 (2006) 1037-1047
12. Koster M.I., et al. p63 induces key target genes required for epidermal morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3255-3260
13. Aberdam D., et al. Key role of p63 in BMP-4-induced epidermal commitment of embryonic stem cells. Cell Cycle 6 (2007) 291-294
14. Senoo M., et al. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129 (2007) 523-536
15. Candi E., et al. DNp63 regulates thymic development through expression of FgfR2 and Jag2. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11999-12004
16. Ou H.D., et al. Structural evolution of C-terminal domains in the p53 family. EMBO J. 26 (2007) 3463-3473
17. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
18. Bourdon J.C., et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19 (2005) 2122-2137
19. Concin N., et al. Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64 (2004) 2449-2460
20. Shinmura K., et al. Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication. Oncogene 26 (2007) 2939-2944
21. Weaver B.A.A., and Cleveland D.W. Does aneuploidy cause cancer?. Curr. Opin. Cell Biol. 18 (2006) 658-667
22. Weaver B.A.A., and Cleveland D.W. Aneuploidy: instigator of inhibitor of tumorigenesis. Cancer Res. 67 (2007) 10103-10105
23. Weaver B.A.A., et al. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11 (2007) 25-36
24. Boveri, T. (1902) Ueber mehrpolige Mitosen als Mittel zur Analyse des Zellkerns Vehr. d. phys. med. Ges. Zu Wurzburg NF (available in English translation at: http://8e.devbio.com/article.php?ch=4&id=24); Bd. 35
25. Babu J.R., et al. Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J. Cell Biol. 160 (2003) 341-353
26. Baker D.J., et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat. Genet. 36 (2004) 744-774
27. Kops G.J., et al. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5 (2005) 773-785
28. Niikura Y., et al. BUB1 mediation of caspase-independent mitotic death determines cell fate. J. Cell Biol. 178 (2007) 283-296
29. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4 (2004) 592-603
30. Lew D.J., et al. The spindle assembly and spindle position checkpoints. Annu. Rev. Genet. 37 (2003) 251-282
31. Rudner A.D., et al. The spindle assembly checkpoint. Curr. Opin. Cell Biol. 8 (1996) 773-780
32. Musacchio A., and Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 8 (2007) 379-393
33. Cahill D.P. Mutations of mitotic checkpoint genes in human cancers. Nature 392 (1998) 300-303
34. Shichiri M., et al. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 62 (2002) 13-17
35. Ohshima K. Mutation analysis of mitotic checkpoint genes (hBUB1 and hBUBR1) and microsatellite instability in adult T-cell leukemia/lymphoma. Cancer Lett. 158 (2000) 141-150
36. Perez de Castro I., et al. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 28 (2007) 899-912
37. Wang X., et al. Mitotic checkpoint defects in human cancers and their implications to chemotherapy. Front. Biosci. 13 (2008) 2103-2114
38. Shih I.M., et al. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res. 61 (2001) 818-822
39. Yuan B., et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin. Cancer Res. 12 (2006) 405-410
40. Grabsch H., et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer - association with tumour cell proliferation. J. Pathol. 200 (2003) 16-22
41. Ouellet V., et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int. J. Cancer 119 (2006) 599-607
42. Kim J.M., et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin. Cancer Res. 11 (2005) 473-482
43. Nishigaki R., et al. Proteomic identification of differentially expressed genes in human gastric carcinomas. Proteomics 5 (2005) 3205-3213
44. Hernando E., et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430 (2004) 797-802
45. Carter S.L., et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38 (2006) 1043-1048
46. Baker D.J., et al. The mitotic checkpoint in cancer and aging: what have mice taught us? Curr. Opin. Cell Biol. 17 (2005) 583-589
47. Burds A.A., et al. Generating chromosome instability through the simultaneous deletion of Mad2 and p53. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11296-11301
48. Wang Q., et al. BUBR1 deficiency results in abnormal megakaryopoiesis. Blood 103 (2004) 1278-1285
49. Jeganathan K., et al. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J. Cell Biol. 179 (2007) 255-267
50. Iwanaga Y., et al. Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res. 67 (2007) 160-166
51. Fukasawa K., et al. Abnormal centrosome amplification in the absence of p53. Science 271 (1996) 1744-1747
52. Duensing A., and Duensing S. Guilt by association? P53 and the development of aneuploidy in cancer. Biochem. Biophys. Res. Commun. 331 (2005) 694-700
53. Vitale I. Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS ONE. 2 (2007) e1337
54. Wang X., et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25 (2006) 7148-7158
55. Kalitsis P., et al. Increased chromosome instability but not cancer predisposition in haploinsufficient Bub3 mice. Genes Chromosome. Canc. 44 (2005) 29-36
56. To-Ho K.W., et al. MAD2ΔC induces aneuploidy and promotes anchorage-independent growth in human prostate epithelial cells. Oncogene 27 (2007) 347-357
57. Okada H., et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J. Exp. Med. 199 (2004) 399-410
58. Oikawa T., et al. Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1. Mol. Cell. Biol. 25 (2005) 4046-4061
59. Ha G.-H., et al. p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation. Cancer Res. 67 (2007) 7155-7164
60. Baek K.H., et al. p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. J. Leukoc. Biol. 73 (2003) 850-861
61. Fang Y., et al. BubR1 is involved in regulation of DNA damage responses. Oncogene 25 (2006) 3598-3605
62. Duensing A., et al. A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress. J. Cell. Biochem. 99 (2006) 759-769
63. Margolis R.L., et al. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J. Cell. Biochem. 88 (2003) 673-683
64. Fulco M., et al. p73 is regulated by phosphorylation at the G2/M transition. J. Biol. Chem. 278 (2003) 49196-49202
65. Merlo P., et al. A role of p73 in mitotic exit. J. Biol. Chem. 280 (2005) 30354-30360
66. Aylon Y., et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev. 20 (2006) 2687-2700
67. Caulin C., et al. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J. Clin. Invest. 117 (2007) 1893-1901
68. Murphy K.L., et al. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 14 (2000) 2291-2293
69. Ciciarello M., et al. p53 displacement from centrosomes and p53-mediated G1 arrest following transient inhibition of the mitotic spindle. J. Biol. Chem. 276 (2001) 19205-19213
70. Talos F., et al. p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol. Cell 27 (2007) 647-659
71. Ravid K., et al. Roads to polyploidy: the megakaryocyte example. J. Cell. Physiol. 190 (2002) 7-20
72. Kossatz U., et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18 (2004) 2602-2607
73. De Laurenzi V.D., et al. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants e and z. Cell Death Differ. 6 (1999) 389-390
74. Zaika A.I., et al. DNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196 (2002) 765-780
75. Tomkova K., et al. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res. 64 (2004) 6390-6393
76. Müller M., et al. TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12 (2005) 1564-1577
77. Concin N., et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin. Cancer Res. 11 (2005) 8372-8383
78. Fillippovich I., et al. Transactivation-deficient p73α (p73Δexon 2) inhibits apoptosis and competes with p53. Oncogene 20 (2001) 514-522
79. Tannapfel A., et al. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor ΔNp73. Carcinogenesis 29 (2008) 211-218
80. Johnson J., et al. p73 loss triggers conversion to squamous cell carcinoma reversible upon reconstitution with TAp73alpha. Cancer Res. 67 (2007) 7723-7730
81. Yang A., et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
82. Flores E.R., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
83. Flores E.R., et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7 (2005) 363-373
84. Irwin M., et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407 (2000) 645-648
85. Innocente S.A., and Lee J.M. p73 is a p53-independent, Sp1-dependent repressor of cyclin B1 transcription. Biochem. Biophys. Res. Commun. 329 (2005) 713-718